Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DZD6008 in Advanced NSCLC With EGFR Mutation (TIAN-SHAN2)
NCT06813365Phase 1Recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Oct 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of DZD6008 in non-small cell lung cancer (NSCLC) (10 arms), sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Safety and Tolerability at 1 year and Anti-tumor Activity at 1 year. Started Jun 2024; status: recruiting.
02
Drugs
DZD6008
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06813365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06813365.